{"id":16907,"date":"2021-08-24T11:48:35","date_gmt":"2021-08-23T22:48:35","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=16907"},"modified":"2021-08-24T11:48:35","modified_gmt":"2021-08-23T22:48:35","slug":"responses-to-covid-19-vaccines-vary-in-patients-with-hematologic-malignancies","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=16907","title":{"rendered":"Responses to COVID-19 Vaccines Vary in Patients With Hematologic Malignancies"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_custom_heading heading_semantic=&#8221;h1&#8243; text_size=&#8221;h1&#8243; uncode_shortcode_id=&#8221;148241&#8243;]<\/p>\n<h1 class=\"post-heading heading\">Responses to COVID-19 Vaccines Vary in Patients With Hematologic Malignancies<\/h1>\n<p>[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;188393&#8243;]<a href=\"https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/hematologic-cancers\/hematologic-malignancy-covid19-vaccine-vary-response-treatment-risk\/\">This article was originally published on Cancer Therapy Advisor\u00a0<\/a><\/p>\n<p>Patients with hematologic malignancies are known to be at risk of severe outcomes from COVID-19, and experts have recommended prioritizing these patients for COVID-19 vaccination.<sup>1,2<\/sup><\/p>\n<p>However, research has suggested that patients with hematologic malignancies may not mount an effective antibody response to vaccination.<sup>3<\/sup><\/p>\n<p>A study recently published in\u00a0<em>Cancer Cell<\/em>\u00a0provides insight into which hematologic malignancies and anticancer treatments confer a greater risk of poor antibody response, as well as which vaccine may be more likely to produce a response in patients with blood cancers.<\/p>\n<p><a href=\"https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/hematologic-cancers\/hematologic-malignancy-covid19-vaccine-vary-response-treatment-risk\/\">To continue reading this article on Cancer Therapy Advisor\u00a0<\/a><\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Research has suggested that patients with hematologic malignancies may not mount an effective antibody response to vaccination.<\/p>\n","protected":false},"author":1,"featured_media":16908,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17,22],"tags":[],"class_list":["post-16907","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","category-covid19"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2021\/08\/CLLCOVID-19.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/16907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16907"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/16907\/revisions"}],"predecessor-version":[{"id":16909,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/16907\/revisions\/16909"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/16908"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}